India reports 38,617 new coronavirus cases; 474 deaths in last 24 hours

Mangalore Today News Network

New Delhi, Nov 18, 2020:    India on Tuesday reported 38,617 new coronavirus cases taking the country’s tally to 89,12,908, as per the Union Health Ministry. With 474 new deaths, the toll has mounted to 1,30,993.

 

The total active cases stand at 4,46,805 after a decrease of 6,596 in the last 24 hours.

The total discharged cases are at 83,35,110 with 44,739 new recoveries in the last 24 hours.

For the eleventh day, India has reported less than 50,000 daily coronavirus cases.

On Tuesday, India reported 29,164 new coronavirus cases taking the toll to 88,74,291, according to the Union Health Ministry.

The last time the daily new cases crossed the 50,000-threshold was on November 7.

"Apart from the successful dissemination of Covid-19 appropriate behaviour among the varied population groups, this trend assumes wider significance as many countries in Europe and America continue to see a surge in their daily numbers," the ministry said in a statement.

Meanwhile, pharmaceutical giant Moderna on Monday announced that its experimental Covid-19 vaccine ’mRNA-1273’ was 94.5 per cent effective in preventing coronavirus. The statement was issued on the basis of interim data from a late-stage clinical trial.

The announcement makes Moderna the second US-based pharmaceutical giant to have reported exceedingly hopeful results from clinical trials of their respective coronavirus vaccine candidates. Just earlier this month, pharma giant Pfizer announced that its Covid-19 experimental vaccine was shown to be more than 90 per cent effective.

According to a press release by Moderna, the "first interim analysis included 95 participants with confirmed cases of Covid-19". The Phase-3 study met statistical criteria with a vaccine efficacy of 94.5 per cent, the statement went on to add.

Moderna now intends to submit for an emergency use authorisation (EUA) with the US FDA. The pharma giant "expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 months".